



Fleur Ferguson

Bio: Prof. Fleur Ferguson received her M.Sc degree in chemistry from Imperial College London, where she received the Department of Chemistry prize for overall excellence. Dr. Ferguson received her Ph.D in chemistry from the University of Cambridge funded by a BBSRC studentship, advised by Prof. Chris Abell and Prof. Alessio Ciulli. She then joined Dana-Farber Cancer Institute at Harvard Medical School, where she performed her postdoctoral research in the laboratory of Prof. Nathanael Gray. Here, her research focused on modulating kinases with reversible inhibitors, covalent inhibitors, and targeted protein degradation, as well as applying TPD to undruggable targets in neurodegeneration. Dr. Ferguson is currently an Assistant Professor in the Department of Chemistry and Biochemistry, and the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego. Her academic research group focuses on the development and application of proximity-pharmacology technologies to disease areas where traditional targeted therapies have failed, such as neurological and degenerative diseases. To translate these discoveries to patients, Dr. Ferguson co-founded a biotechnology company, and her lab collaborates with scientists in the pharmaceutical industry, and physicians in the Department of Medicine. Research in the Ferguson lab has been recognized by numerous prestigious awards including the NIH Directors' New Innovator Award, the NSF CAREER, the Keck Foundation Research Award, and new investigator awards from the Alzheimer's Association, the PhRMA Foundation, and the Hilblom Foundation.